Literature DB >> 22261337

Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.

Jui-Ling Hsu1, Pui-Kei Leong1, Yunn-Fang Ho1, Lih-Ching Hsu1, Pin-Hsuan Lu1, Ching-Shih Chen2, Jih-Hwa Guh3.   

Abstract

The knockdown of Pim-1 or inhibition of Pim-1 activity significantly increased γ-H2A.X expression. The effect was correlated to apoptosis and was attributed to the inhibition of nonhomologous DNA-end-joining (NHEJ) repair activity supported by the following observations: (1) inhibition of ATM and DNA-PKcs activities, (2) down-regulation of Ku expression and nuclear localization and (3) decrease of DNA end-binding of both Ku70 and Ku80. The data suggest that Pim-1 plays a crucial role in the regulation of NHEJ repair. In the absence of Pim-1, the ability of DNA repair significantly decreases when exposed to paclitaxel, leading to severe DNA damage and apoptosis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261337      PMCID: PMC4207118          DOI: 10.1016/j.canlet.2012.01.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  38 in total

1.  The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C.

Authors:  Malte Bachmann; Christian Kosan; Pei Xiang Xing; Mathias Montenarh; Ingrid Hoffmann; Tarik Möröy
Journal:  Int J Biochem Cell Biol       Date:  2005-11-08       Impact factor: 5.085

2.  Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.

Authors:  Yong Xu; Tong Zhang; Hua Tang; Shumin Zhang; Min Liu; Dalin Ren; Yuanjie Niu
Journal:  J Surg Oncol       Date:  2005-12-15       Impact factor: 3.454

3.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.

Authors:  Y Xie; K Xu; B Dai; Z Guo; T Jiang; H Chen; Y Qiu
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

4.  Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.

Authors:  Zeping Wang; Nandini Bhattacharya; Philip F Mixter; Wenyi Wei; John Sedivy; Nancy S Magnuson
Journal:  Biochim Biophys Acta       Date:  2002-12-16

5.  Pim family kinases enhance tumor growth of prostate cancer cells.

Authors:  Wei Wei Chen; Daniel C Chan; Carlton Donald; Michael B Lilly; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2005-08       Impact factor: 5.852

6.  Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.

Authors:  Kevin C Qian; Lian Wang; Eugene R Hickey; Joey Studts; Kevin Barringer; Charline Peng; Anthony Kronkaitis; Jun Li; Andre White; Sheenah Mische; Bennett Farmer
Journal:  J Biol Chem       Date:  2004-11-03       Impact factor: 5.157

Review 7.  Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.

Authors:  Lisa S Chen; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

8.  Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.

Authors:  Sarah R Walker; Mousumi Chaudhury; Erik A Nelson; David A Frank
Journal:  Mol Pharmacol       Date:  2010-08-06       Impact factor: 4.436

9.  Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation.

Authors:  Teija L T Aho; Riikka J Lund; Emmi K Ylikoski; Sampsa Matikainen; Riitta Lahesmaa; Päivi J Koskinen
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

10.  Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL.

Authors:  Andrew Macdonald; David G Campbell; Rachel Toth; Hilary McLauchlan; C James Hastie; J Simon C Arthur
Journal:  BMC Cell Biol       Date:  2006-01-10       Impact factor: 4.241

View more
  10 in total

Review 1.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

2.  Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer.

Authors:  Jiang Wang; Gang Li; Bo Li; Hualin Song; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

3.  The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM.

Authors:  Shahar Zirkin; Ateret Davidovich; Jeremy Don
Journal:  J Biol Chem       Date:  2013-06-11       Impact factor: 5.157

4.  PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.

Authors:  Esperanza Martín-Sánchez; Lina Odqvist; Socorro M Rodríguez-Pinilla; Margarita Sánchez-Beato; Giovanna Roncador; Beatriz Domínguez-González; Carmen Blanco-Aparicio; Ana M García Collazo; Esther González Cantalapiedra; Joaquín Pastor Fernández; Soraya Curiel del Olmo; Helena Pisonero; Rebeca Madureira; Carmen Almaraz; Manuela Mollejo; F Javier Alves; Javier Menárguez; Fernando González-Palacios; José Luis Rodríguez-Peralto; Pablo L Ortiz-Romero; Francisco X Real; Juan F García; James R Bischoff; Miguel A Piris
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

5.  In vitro evaluation of dihydropyridine-3-carbonitriles as potential cytotoxic agents through PIM-1 protein kinase inhibition.

Authors:  Khalil Abnous; Hesam Manavi; Soghra Mehri; Mona Alibolandi; Hossein Kamali; Morteza Ghandadi; Farzin Hadizadeh
Journal:  Res Pharm Sci       Date:  2017-06

6.  The T850D Phosphomimetic Mutation in the Androgen Receptor Ligand Binding Domain Enhances Recruitment at Activation Function 2.

Authors:  Christine Helsen; Tien Nguyen; Thomas Vercruysse; Staf Wouters; Dirk Daelemans; Arnout Voet; Frank Claessens
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

7.  Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.

Authors:  Kshama A Doshi; Rossana Trotta; Karthika Natarajan; Feyruz V Rassool; Adriana E Tron; Dennis Huszar; Danilo Perrotti; Maria R Baer
Journal:  Oncotarget       Date:  2016-07-26

Review 8.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 9.  DNA Damage and Repair in Pulmonary Arterial Hypertension.

Authors:  Samantha Sharma; Micheala A Aldred
Journal:  Genes (Basel)       Date:  2020-10-19       Impact factor: 4.096

10.  PIM1 phosphorylation of the androgen receptor and 14-3-3 ζ regulates gene transcription in prostate cancer.

Authors:  Sophie E Ruff; Nikita Vasilyev; Evgeny Nudler; Susan K Logan; Michael J Garabedian
Journal:  Commun Biol       Date:  2021-10-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.